The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Post-authorization safety of lenalidomide+dexamethasone in patients with multiple myeloma in Turkey
Meral Beksac, MD, Ankara University, Ankara, Turkey, gives an overview of the results of a study evaluating the post-authorization safety of the combination of lenalidomide and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma in Turkey, discussing the incidence of venous thromboembolism (VTE), second primary malignancy (SPM), and treatment discontinuation. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
